CoChat

Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease

Open access

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

Background: Age is the strongest risk factor for the development of Alzheimer’s disease (AD). Besides the pathological hallmarks of β-amyloid (Aβ) plaques and neurofibrillary tangles, emerging evidence demonstrates a critical role of microglia and neuroinflammation in AD pathogenesis. Oleoylethanolamide (OEA) is an endogenous lipid amide that has been shown to promote lifespan and healthspan in C. elegans through regulation of lysosome-to-nucleus signaling and cellular metabolism. The goal of our study was to determine the role of OEA in the mediation of microglial activity and AD pathology using its stable analog, KDS-5104. Methods: We used primary microglial cultures and genetic and pharmacological approaches to examine the signaling mechanisms and functional roles of OEA in mediating Aβ phagocytosis and clearance, lipid metabolism and inflammasome formation. Further, we tested the effect of OEA in vivo in acute LPS-induced neuroinflammation and by chronic treatment of 5xFAD mice. Results: We found that OEA activates PPARα signaling and its downstream cell-surface receptor CD36 activity. In addition, OEA promotes TFEB lysosomal function in a PPARα-dependent but mTORC1-independent manner, the combination of which leads to enhanced microglial Aβ uptake and clearance. These are associated with the suppression of LPS-induced lipid droplet accumulation and inflammasome activation. Chronic treatment of 5xFAD mice with KDS-5104 restored dysregulated lipid profiles, reduced reactive gliosis and Aβ pathology and rescued cognitive impairments. Conclusion: Together, our study provides support that augmenting OEA-mediated lipid signaling may offer therapeutic benefit against aging and AD through modulating lipid metabolism and microglia phagocytosis and clearance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-023-00648-x

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 KDS-5104 activates PPARα and TFEB signaling in microglial cells. (a) qPCR analysis of expression of Ppara and downstream target Cyp4a14 in sorted microglia isolated from brains of 9-month-old 5xFAD and WT littermates (n = 5/group). (b) qPCR analysis of Tfeb and downstream target Mcoln1 of the same samples as a) (n = 5/group). c. qPCR analysis of PPARA and CYP4A11 expression in KDS-5104 treated WT and TKO HeLa cells (n = 9/condition). d. qPCR analysis of Tfeb and Mcoln1 in WT and PPARαKO primary microglial cultures (n = 8/condition). e. qPCR analysis of Tfeb and Mcoln1 in vehicle or KDS-5104 treated BV2 cells with or without pretreatment with PPARα antagonist GW6471 (n = 8/condition). f. Model of KDS-5104 action of PPARα activation and TFEB signaling. For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001 by 2-sided t tests (a, b) or one way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis (c-e)
Fig. 1 KDS-5104 activates PPARα and TFEB signaling in microglial cells. (a) qPCR analysis of expression of Ppara and downstream target Cyp4a14 in sorted microglia isolated from brains of 9-month-old 5xFAD and WT littermates (n = 5/group). (b) qPCR analysis of Tfeb and downstream target Mcoln1 of the same samples as a) (n = 5/group). c. qPCR analysis of PPARA and CYP4A11 expression in KDS-5104 treated WT and TKO HeLa cells (n = 9/condition). d. qPCR analysis of Tfeb and Mcoln1 in WT and PPARαKO primary microglial cultures (n = 8/condition). e. qPCR analysis of Tfeb and Mcoln1 in vehicle or KDS-5104 treated BV2 cells with or without pretreatment with PPARα antagonist GW6471 (n = 8/condition). f. Model of KDS-5104 action of PPARα activation and TFEB signaling. For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001 by 2-sided t tests (a, b) or one way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis (c-e)CC BY · PubMed Central
Fig. 2 KDS-5104 increases TFEB lysosomal genes independent of mTORC1. (a) qPCR analysis of lysosome enzyme genes LAMP1, NEU1, and NAGLU in vehicle or KDS-5104 treated WT and TKO cells (n = 8/condition). (b) qPCR analysis of Lamp1, Neu1, Naglu in vehicle or KDS-5104 treated WT and PPARαKO primary microglia cultures (n = 10/condition). (c) Western blot analysis of total and phosphorylated S6K (pS6K) levels in primary microglial cultures treated with vehicle (Control), KDS-5104 (10 µM) or Torin (500 nM). γ-tubulin was used as a loading control. (d) Quantification of pS6k expression level normalized to γ-tubulin (left) and the ratio of pS6k to total S6k (right) (n = 6/condition). AU: artificial unit. For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis
Fig. 2 KDS-5104 increases TFEB lysosomal genes independent of mTORC1. (a) qPCR analysis of lysosome enzyme genes LAMP1, NEU1, and NAGLU in vehicle or KDS-5104 treated WT and TKO cells (n = 8/condition). (b) qPCR analysis of Lamp1, Neu1, Naglu in vehicle or KDS-5104 treated WT and PPARαKO primary microglia cultures (n = 10/condition). (c) Western blot analysis of total and phosphorylated S6K (pS6K) levels in primary microglial cultures treated with vehicle (Control), KDS-5104 (10 µM) or Torin (500 nM). γ-tubulin was used as a loading control. (d) Quantification of pS6k expression level normalized to γ-tubulin (left) and the ratio of pS6k to total S6k (right) (n = 6/condition). AU: artificial unit. For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysisCC BY · PubMed Central
Fig. 3 KDS-5104 increases lysosomal biogenesis in a PPARα dependent manner. (a) Representative LAMP1 immunofluorescence images of vehicle or KDS-5104 treated BV2 cells with or without GW6471 pretreatment. (b) Quantification of LAMP1 fluorescent intensity (n = 6/condition). (c) Representative images of LAMP1 (green) and DAPI (white) staining and corresponding 3D renderings of primary WT and PPARαKO microglia cultures treated with vehicle or 10 µM KDS-5104 for 8 h. (d) Quantification of lysosome size, number of lysosomes per cell and distance of lysosomes from the nucleus. (e) Representative images of lysotracker positive lysosomes and 3D renderings of primary WT and PPARαKO microglial cultures treated with vehicle or 10 µM KDS-5104 for 8 h. (f) Quantification of lysotracker fluorescence intensity and number of lysotracker + lysosomes per cell. Approximately 25 cells obtained from a minimum of 3 wells per group were analyzed. AU: artificial unit. Scale bars: 200 μm in (a) and 100 μm in (c, e). For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis
Fig. 3 KDS-5104 increases lysosomal biogenesis in a PPARα dependent manner. (a) Representative LAMP1 immunofluorescence images of vehicle or KDS-5104 treated BV2 cells with or without GW6471 pretreatment. (b) Quantification of LAMP1 fluorescent intensity (n = 6/condition). (c) Representative images of LAMP1 (green) and DAPI (white) staining and corresponding 3D renderings of primary WT and PPARαKO microglia cultures treated with vehicle or 10 µM KDS-5104 for 8 h. (d) Quantification of lysosome size, number of lysosomes per cell and distance of lysosomes from the nucleus. (e) Representative images of lysotracker positive lysosomes and 3D renderings of primary WT and PPARαKO microglial cultures treated with vehicle or 10 µM KDS-5104 for 8 h. (f) Quantification of lysotracker fluorescence intensity and number of lysotracker + lysosomes per cell. Approximately 25 cells obtained from a minimum of 3 wells per group were analyzed. AU: artificial unit. Scale bars: 200 μm in (a) and 100 μm in (c, e). For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysisCC BY · PubMed Central
Fig. 4 KDS-5104-PPARα pathway promotes phagocytosis and Aβ clearance. (a) Representative images of fluorescent beads (green) uptake in Iba1 (red) positive WT and PPARαKO primary microglia cultures treated with vehicle or 10 µM KDS-5104 for 8 h. (b) Quantification of the percentage of microglia positive cells with fluorescent beads (n = 6/condition). (c) Representative images of CD36 (green) and Iba1 (red) staining in primary WT and PPARαKO microglia cultures treated with vehicle or KDS-5104. (d) Quantification of CD36 fluorescence intensity per cell of ~ 100 cells (n = 7–9/condition). (e) Time course of fluorescent labeled Aβ (green) and DAPI (white) in vehicle or KDS-5104 treated WT microglial cultures with or without pretreatment with the CD36 neutralizing antibody. (f) Analysis of Aβ fluorescence intensity per cell of ~ 100 cells at time of zero of Aβ removal (n = 6/condition). (g) Quantification of the percentage of baseline fluorescence remaining 1 h, 2 h, and 4 h after the removal of Aβ (n = 6/condition). Scale bars: 100 μm. For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis
Fig. 4 KDS-5104-PPARα pathway promotes phagocytosis and Aβ clearance. (a) Representative images of fluorescent beads (green) uptake in Iba1 (red) positive WT and PPARαKO primary microglia cultures treated with vehicle or 10 µM KDS-5104 for 8 h. (b) Quantification of the percentage of microglia positive cells with fluorescent beads (n = 6/condition). (c) Representative images of CD36 (green) and Iba1 (red) staining in primary WT and PPARαKO microglia cultures treated with vehicle or KDS-5104. (d) Quantification of CD36 fluorescence intensity per cell of ~ 100 cells (n = 7–9/condition). (e) Time course of fluorescent labeled Aβ (green) and DAPI (white) in vehicle or KDS-5104 treated WT microglial cultures with or without pretreatment with the CD36 neutralizing antibody. (f) Analysis of Aβ fluorescence intensity per cell of ~ 100 cells at time of zero of Aβ removal (n = 6/condition). (g) Quantification of the percentage of baseline fluorescence remaining 1 h, 2 h, and 4 h after the removal of Aβ (n = 6/condition). Scale bars: 100 μm. For all panels, data are presented as mean ± SEM. ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysisCC BY · PubMed Central
Fig. 5 KDS-5104 reduces LPS-induced inflammation and lipid droplet formation via PPARα activation. (a) Representative images of Iba1 and GFAP from 4-month-old WT and PPARαKO mice pretreated with vehicle or 10 mg/kg KDS-5104 (i.p.) for 24 h, followed by a co-treatment of LPS (2 mg/kg, i.p.) and KDS-5104 (10 mg/kg, i.p.) for 18 h. (b) Quantification of GFAP fluorescent area (n = 5 mice/group). (c) Quantification of Iba1 fluorescent area (n = 5 mice/group). (d) Representative images of ASC speck (red) in primary WT and PPARαKO microglia cultures pretreated with vehicle or KDS-5104 for 18 h before addition of LPS. (e) Quantification of percentage of ASC positive cells (n = 9/group). (f) Same as (d) except BODIPY + lipid droplet was imaged. (g) Quantification of percentage of BODIPY positive cells (n = 6/group). (h) Representative images of lipid droplet formation by BODIPY (red) and DAPI (white) in vehicle or KDS-5104 pretreated and LPS induced BV2 cells without or with GW6471. (i) Quantification of percentage of BODIPY cells (n = 12/group). Scale bar: 100 μm. For all panels, data are presented as mean ± SEM. ns: non- significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis
Fig. 5 KDS-5104 reduces LPS-induced inflammation and lipid droplet formation via PPARα activation. (a) Representative images of Iba1 and GFAP from 4-month-old WT and PPARαKO mice pretreated with vehicle or 10 mg/kg KDS-5104 (i.p.) for 24 h, followed by a co-treatment of LPS (2 mg/kg, i.p.) and KDS-5104 (10 mg/kg, i.p.) for 18 h. (b) Quantification of GFAP fluorescent area (n = 5 mice/group). (c) Quantification of Iba1 fluorescent area (n = 5 mice/group). (d) Representative images of ASC speck (red) in primary WT and PPARαKO microglia cultures pretreated with vehicle or KDS-5104 for 18 h before addition of LPS. (e) Quantification of percentage of ASC positive cells (n = 9/group). (f) Same as (d) except BODIPY + lipid droplet was imaged. (g) Quantification of percentage of BODIPY positive cells (n = 6/group). (h) Representative images of lipid droplet formation by BODIPY (red) and DAPI (white) in vehicle or KDS-5104 pretreated and LPS induced BV2 cells without or with GW6471. (i) Quantification of percentage of BODIPY cells (n = 12/group). Scale bar: 100 μm. For all panels, data are presented as mean ± SEM. ns: non- significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysisCC BY · PubMed Central
Fig. 6 Reversed lipid dysregulation in 5xFAD mice with KDS-5104 treatment. (a) qPCR analysis of Ppara, Cyp4a14, Tfeb and Mcoln1 in 4-month-old WT and 5xFAD mice treated with vehicle or KDS-5104 for 2 months (n = 9/group). (b) Heatmap representing z scores of top 55 dysregulated lipid species in 5xFAD mice identified by lipidomic analysis of 4-month-old WT and 5xFAD mice treated with vehicle or KDS-5104. (c) Normalized levels of the lipid species per lipid class (n = 5 mice/group). PE: phosphatidylethanolamine, PC: phosphatidycholine, PS: phosphatidylserine, DG: diglycerides, and TG: trigylcerides (TG). (d) Pie chart depicting the classes of the 156 lipids identified that are dysregulated in 5xFAD mice compared to WT and rescued with KDS-5104 treatment. CoQ: Coenzyme Q10, LPE: Lysophosphatidylethanolamine, SM: Sphingomyelin, and PI: Phosphatidylinositol. For all panels, data are presented as mean ± SEM. #p = 0.2 in (a) and 0.1 in (c), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis
Fig. 6 Reversed lipid dysregulation in 5xFAD mice with KDS-5104 treatment. (a) qPCR analysis of Ppara, Cyp4a14, Tfeb and Mcoln1 in 4-month-old WT and 5xFAD mice treated with vehicle or KDS-5104 for 2 months (n = 9/group). (b) Heatmap representing z scores of top 55 dysregulated lipid species in 5xFAD mice identified by lipidomic analysis of 4-month-old WT and 5xFAD mice treated with vehicle or KDS-5104. (c) Normalized levels of the lipid species per lipid class (n = 5 mice/group). PE: phosphatidylethanolamine, PC: phosphatidycholine, PS: phosphatidylserine, DG: diglycerides, and TG: trigylcerides (TG). (d) Pie chart depicting the classes of the 156 lipids identified that are dysregulated in 5xFAD mice compared to WT and rescued with KDS-5104 treatment. CoQ: Coenzyme Q10, LPE: Lysophosphatidylethanolamine, SM: Sphingomyelin, and PI: Phosphatidylinositol. For all panels, data are presented as mean ± SEM. #p = 0.2 in (a) and 0.1 in (c), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysisCC BY · PubMed Central
Fig. 7 Reduced reactive gliosis and Aβ pathology in 5xFAD mice treated with KDS-5104. (a) Representative images of GFAP (magenta) and Iba1 (yellow) co-staining from the hippocampal sections of 4-month-old 5xFAD and WT mice treated with vehicle or 10 mg/kg KDS-5104 for two months. Scale bar:. (b) Quantification of Iba1 and GFAP area fluorescence (n = 5–6 mice/group). (c) Representative images of 6E10 (white) of hippocampal sections of 4-month-old 5xFAD treated with vehicle or KDS-5104. (d) Quantification of 6E10 positive area and plaque number (n = 5–6 mice/group). (e) Representative images of CD68 (red), Iba1 (yellow) and 6E10 (white) co-staining and 3D rendering created by Imaris imaging software. f-h. Quantification of plaque size (f), CD68 fluorescent intensity (g), microglia per plaque (h) and microglia area (i)(n = 5–6 mice/group). AU: artificial unit. Scale bar: 100 μm in (a) and (c) and 10 μm in (e). For all panels, data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis (panel b) or 2-sided t-tests (panels d and f-i)
Fig. 7 Reduced reactive gliosis and Aβ pathology in 5xFAD mice treated with KDS-5104. (a) Representative images of GFAP (magenta) and Iba1 (yellow) co-staining from the hippocampal sections of 4-month-old 5xFAD and WT mice treated with vehicle or 10 mg/kg KDS-5104 for two months. Scale bar:. (b) Quantification of Iba1 and GFAP area fluorescence (n = 5–6 mice/group). (c) Representative images of 6E10 (white) of hippocampal sections of 4-month-old 5xFAD treated with vehicle or KDS-5104. (d) Quantification of 6E10 positive area and plaque number (n = 5–6 mice/group). (e) Representative images of CD68 (red), Iba1 (yellow) and 6E10 (white) co-staining and 3D rendering created by Imaris imaging software. f-h. Quantification of plaque size (f), CD68 fluorescent intensity (g), microglia per plaque (h) and microglia area (i)(n = 5–6 mice/group). AU: artificial unit. Scale bar: 100 μm in (a) and (c) and 10 μm in (e). For all panels, data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis (panel b) or 2-sided t-tests (panels d and f-i)CC BY · PubMed Central
Fig. 8 Improved synaptic properties and cognitive performance in 5xFAD mice treated with KDS-5104. (a) Representative images of co-staining of post-synaptic marker PSD95 and presynaptic marker synaptophysin (Syp) from hippocampal CA1 area of 4-month-old WT and 5xFAD mice treated with vehicle or 10 mg/kg KDS-5104. Inset showing enlarged view of Syp and PSD95 co-localized puncta. Scale bar: 100 μm; 25 μm zoom in. (b) Quantification of the number of PSD95, Syp and co-localized Syp and PSD95 puncta (n = 6 mice/group). (c) Quantification of percent time exploring the novel object in NOR assay. (d) Freezing percentage due to contextual or cue testing in the fear conditioning paradigm (n = 11–13 mice/group). For all panels, data are presented as mean ± SEM. ns: non- significant, #p = 0.11, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysis
Fig. 8 Improved synaptic properties and cognitive performance in 5xFAD mice treated with KDS-5104. (a) Representative images of co-staining of post-synaptic marker PSD95 and presynaptic marker synaptophysin (Syp) from hippocampal CA1 area of 4-month-old WT and 5xFAD mice treated with vehicle or 10 mg/kg KDS-5104. Inset showing enlarged view of Syp and PSD95 co-localized puncta. Scale bar: 100 μm; 25 μm zoom in. (b) Quantification of the number of PSD95, Syp and co-localized Syp and PSD95 puncta (n = 6 mice/group). (c) Quantification of percent time exploring the novel object in NOR assay. (d) Freezing percentage due to contextual or cue testing in the fear conditioning paradigm (n = 11–13 mice/group). For all panels, data are presented as mean ± SEM. ns: non- significant, #p = 0.11, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. One way ANOVA with Tukey’s multiple comparisons tests as the post hoc analysisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 33

Metadata

Authors
Comerota, M. M., Gedam, M., Xiong, W., Jin, F., Deng, L., Wang, M. C., Wang, J., & Zheng, H.
Affiliations
  • Baylor College of Medicine (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Zheng, Hui
Venue
Molecular Neurodegeneration
Published
2023-08-15
Volume
18
Issue
1
Pages
56-56
ISSN
1750-1326 (ISSN-L)
OpenAlex
W4385803674
Cited by
31
References
61
Citations by year
2026: 7 · 2025: 12 · 2024: 7 · 2023: 5
FWCI
5.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute on Aging (P01AG066606, RF1AG062257, RF1AG020670)
  • National Institute of Neurological Disorders and Stroke (RF1NS093652)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
oleoylethanolamide, Alzheimer's disease, PPARα signaling, TFEB, lysosomal function, microglia, amyloid-beta clearance, CD36, lipid metabolism, inflammasome, neuroinflammation, 5xFAD mice, lipid droplets, reactive gliosis, cognitive impairment
MeSH terms
Neuroinflammatory Diseases, Alzheimer Disease, Animals, Disease Models, Animal, Lipopolysaccharides, Mice, Transgenic, Oleic Acids, Amyloid beta-Peptides, Caenorhabditis elegans, Microglia, PPAR alpha, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Inflammasomes, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13024-023-00648-x
The paper
Comerota, M. M., Gedam, M., Xiong, W., Jin, F., Deng, L., Wang, M. C., Wang, J., & Zheng, H. (2023). Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00648-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.